Merck Eyes $3B Acquisition of EyeBio for Ophthalmology Expansion
Merck is set to acquire EyeBio, an ophthalmology-focused biotech company, for up to $3 billion, including an upfront payment of $1.3 billion and potential milestone payments. The acquisition includes EyeBio's lead candidate, Restoret™, which targets diabetic macular edema and neovascular age-related macular degeneration, and is expected to enter pivotal trials in late 2024. This move aims to expand Merck's pipeline and presence in ophthalmology.
